Compare Regeneron Pharmaceuticals Inc (REGN) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Yum China Holdings Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Yum China Holdings Inc trades at $43.29 (market cap $14.69B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.8× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays the higher dividend (2.71%). Which is the better fit depends on your goals.
| REGN | YUMC | |
|---|---|---|
Market Cap | $70.79B | $14.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $812.27 | $57.95 |
52-Week Low | $545.46 | $40.18 |
Enterprise Value | $64.74B | $15.57B |
Dividend Yield | 0.56% | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
YUMC trades at $42.77, down 2.51% today, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company shows consistent revenue growth, reaching $11.80B in 2025, and has beaten earnings estimates in three consecutive quarters. Recent strategic moves include the acquisition of Pizza Hut China, enhancing local control and cost synergies. Analyst sentiment remains strongly positive with 14 buy ratings and no sell recommendations.
The outlook for YUMC is favorable due to solid fundamentals and strategic initiatives, though risks include macroeconomic headwinds in China and competitive pressures. Valuation metrics like a P/E of 16.83 and EV/EBITDA of 8.76 suggest reasonable pricing relative to earnings, supporting potential upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
